Multiplex Serological Assays for COVID-19

Listen to Cerus Chief Scientific Officer Larry Corash who joined the Sino Biological-hosted webinar entitled Multiplex Serological Assays for COVID-19.
A full replay is available here

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage. Follow us on LinkedIn.

Cerus.com

INTERCEPT-USA.com

HCP.INTERCEPT-USA.com

INTERCEPT-Canada.com

INTERCEPTBloodSystem.com

INTERCEPT-Cryoprecipitation.com

Multiplex Serological Assays for COVID-19

Recent Posts

Recent Comments

About Cerus